Previously, the Wnt-antagonist DKK-1 has been implicated in reduced bone formation activity in multiple myeloma [28] and in animal models of prostate cancer bone metastasis [29] where it may regulate the transition between osteolytic and osteoblastic phenotypes [51]. Here, DKK1 is linked to plasma cell myeloma.